España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Aptose Biosciences
APTO
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.190000
-0.05
-22.13%
At close: -
$0.172000
-0.02
-9.47%
After Hours: 7:59 PM EDT
Get Report
Comment
Aptose Biosciences (APTO) Forecast
News
Earnings
Aptose Biosciences (APTO) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Aptose Biosciences (NASDAQ:APTO) Stock
Aptose Biosciences Stock (NASDAQ: APTO)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, November 22, 2024
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
Avi Kapoor
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views
Avi Kapoor
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
Avi Kapoor
Aptose Biosciences shares are trading lower a...
Benzinga Newsdesk
Aptose Biosciences Prices $8M Public Offering...
Benzinga Newsdesk
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Wednesday, November 20, 2024
HC Wainwright & Co. Maintains Buy on Aptose B...
Benzinga Newsdesk
Aptose Biosciences Announced Initiation Of Th...
Benzinga Newsdesk
Friday, November 08, 2024
Aptose Biosciences Q3 2024 GAAP EPS $(0.37) B...
Benzinga Newsdesk
Tuesday, September 03, 2024
Aptose shares are trading higher after the co...
Benzinga Newsdesk
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday
Avi Kapoor
Friday, August 30, 2024
Aptose shares are trading higher after the co...
Benzinga Newsdesk
Aptose Biosciences Secures $10M Loan From Han...
Benzinga Newsdesk
Thursday, August 08, 2024
Aptose Biosciences Q2 2024 GAAP EPS $(0.43) B...
Benzinga Newsdesk
Friday, June 14, 2024
HC Wainwright & Co. Reiterates Buy on Aptose ...
Benzinga Newsdesk
Aptose Showcases Clinical And Preclinical Res...
Benzinga Newsdesk
Thursday, June 13, 2024
Aptose Biosciences Shares Move Higher; Trader...
Benzinga Newsdesk
Friday, May 31, 2024
Aptose Announces $4.43M Registered Direct Off...
Benzinga Newsdesk
Thursday, May 16, 2024
Canaccord Genuity Maintains Buy on Aptose Bio...
Benzinga Newsdesk
Tuesday, May 14, 2024
Aptose Biosciences Q1 EPS $(0.73) Beats $(0.7...
Benzinga Newsdesk
Wednesday, April 03, 2024
Piper Sandler Maintains Overweight on Aptose ...
Benzinga Newsdesk
Wednesday, March 27, 2024
HC Wainwright & Co. Maintains Buy on Aptose B...
Benzinga Newsdesk
Tuesday, March 26, 2024
Aptose Biosciences Q4 EPS $(1.44) Beats $(1.5...
Benzinga Newsdesk
Recap: Aptose Biosciences Q4 Earnings
Benzinga Insights
Aptose Reports FY23 Loss Per Share Of $(7.58)...
Benzinga Newsdesk
Earnings Scheduled For March 26, 2024
Benzinga Insights
Monday, March 25, 2024
Aptose Biosciences's Earnings: A Preview
Benzinga Insights
Thursday, February 01, 2024
Piper Sandler Maintains Overweight on Aptose ...
Benzinga Newsdesk
Friday, January 26, 2024
Aptose Announces Pricing Of Underwritten Offe...
Benzinga Newsdesk
Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Sunday, December 10, 2023
Aptose Tuspetinib Clinical Data Featured In Oral Presentation Saturday At 2023 ASH Meeting; Said TUS/VEN Combination Active Across Broad Populations Of AML And Demonstrates 25% Complete Response Rate Among All-comers, Including 20% CRc In Wildtype AML
Charles Gross
Monday, December 04, 2023
Aptose Biosciences Files For Offering 4.1M Co...
Benzinga Newsdesk
Friday, November 10, 2023
RBC Capital Maintains Outperform on Aptose Bi...
Benzinga Newsdesk
Thursday, November 09, 2023
Aptose Biosciences: Q3 Earnings Insights
Benzinga Insights
Aptose Biosciences Q3 EPS $(1.76) Beats $(2.0...
Benzinga Newsdesk
Earnings Scheduled For November 9, 2023
Benzinga Insights
Thursday, November 02, 2023
Aptose Tuspetinib Clinical Data Selected For ...
Benzinga Newsdesk
Monday, October 30, 2023
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
Monday, October 16, 2023
Aptose Biosciences shares are trading higher ...
Benzinga Newsdesk
Aptose Biosciences Announced That Two Abstrac...
Benzinga Newsdesk
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Thursday, September 07, 2023
Expert Ratings for Aptose Biosciences
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ap...
Benzinga Newsdesk
Friday, August 11, 2023
Piper Sandler Maintains Overweight on Aptose ...
Benzinga Newsdesk
RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know
Benzinga Insights
RBC Capital Maintains Outperform on Aptose Bi...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Aptose B...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Aptose Bi...
Benzinga Newsdesk
Thursday, August 10, 2023
Aptose Biosciences Q2 EPS $(2.27) Misses $(2....
Benzinga Newsdesk
Show More